Migren': vozmozhnosti profilakticheskogo lecheniya
- Authors: Kamchatnov P.R1, Chugunov A.V1, Glushkova K.S1
-
Affiliations:
- ГОУ ВПО Российский государственный медицинский университет, Москв
- Issue: Vol 10, No 2 (2008)
- Pages: 87-90
- Section: Articles
- URL: https://ogarev-online.ru/2075-1753/article/view/92646
- ID: 92646
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
P. R Kamchatnov
ГОУ ВПО Российский государственный медицинский университет, МосквКафедра неврологии и нейрохирургии лечебного факультета
A. V Chugunov
ГОУ ВПО Российский государственный медицинский университет, МосквКафедра неврологии и нейрохирургии лечебного факультета
K. S Glushkova
ГОУ ВПО Российский государственный медицинский университет, МосквКафедра неврологии и нейрохирургии лечебного факультета
References
- Lipton R, Stewart W. Prevalence and burden of migraine in the United States: data from the American migraine study II. Headache 2001; 41: 646–57.
- Stewart W, Shechter A, Rasmussen B. Migraine prevalence. A review of population - based studies. Neurology 1994; 44 (suppl. 4): S17–23.
- Edmeads J, Mackell J. The economic impact of migraine: an analysis of direct and indirect costs. Headache 2002; 42: 501–9.
- Hu X, Markson L, Lipton R et al. Burden of migraine in the United States: disability and economic costs. Arch Intern Med 1999; 159: 813–8.
- Вейн A.M., Koлocoвa O.A. и др. Мигрень. M., 1995.
- Cao Y, Autiora S, Vikingstad E, Welch K. Functional MRI (fMRI) of visually triggered headache. Activation, suppression and propagation of "bold" effect. J Cereb Blood Flow Metab 1997; 17 (suppl.): 176–9.
- Anderson A, Friberg L, Olesen T, Olson J. SPECT demonstration of delayed hyperemia following hypoperfusion in classic migraine. Arch Neurol 1988; 45: 154–59.
- Woods R, Iacoboni M, Mazziotta J. Bilateral spreading cerebral hypoperfusion during spontaneous migraine headache. N Engl J Med 1994; 331: 1689–92.
- Goadsby P, Edmundson L, Ekman R. Vasoactive peptide release in extracerebral circulation of humans during migraine headache. Ann Neurol 1990; 28: 183–7.
- Амелин А.В., Скоромец А.А., Игнатов Ю.Д. Роль серотонина и серотониновых рецепторов в патогенезе мигрени и механизмах действия антимигренозных препаратов. Журн. неврол. и психиатр. им. С.С.Корсакова. 2000; 7: 55–8.
- Fozard J. Serotonin, migraine and platelets. Progressive Pharmacol 1982; 414: 135–46.
- Silberstein S. Serotonin (5-HT) and Migraine. (Review). Headache 1994; 34: 408–17.
- Randall A, Benham C. Recent advances in the molecular understanding of voltage - gated Ca(2+) channels. Mol Cell Neurosci 1999; 14: 255–72.
- Welch K, De'andrea G, Tepley L et al. The concept of migraine as a state of central neuronal hyperexcitability. Neurol Clin 1990; 8: 817–28.
- Schoenen J, Wang W, Albert A, Delwaide P. Potentiation instead of habituation characterizes visual evoked potentials in migraine patients between attacks. Eur J Neurol 1995; 2: 115–22.
- Kors E, Terwindt G, Vermeulen F et al. Delayed cerebral edema and fatal coma after minor head trauma: role of the CACNA1A calcium channel subunit gene and relationship with familial hemiplegic migraine. Ann Neurol 2001; 49: 753–60.
- Limmorth V, Cutrer P, Moskowitz A. Neurotransmitters and neuropeptides in headache. Curr Opin Neurol l996; 9: 206–10.
- Kaniecki R, Totten J. Cervicalgia in migraine: prevalence, clinical characteristics and response for treatment. Cephalalgia 2001; 21: 296–7.
- Kibler J, Rhudy J, Penzien D et al. Hormones, Menstrual Distress, and Migraine Across the Phases of the Menstrual Cycle Headache: The Journal of Head and Face Pain 2005; 45 (9): 1181–7.
- Goadsby P, Lipton R, Ferrari M. Migraine – Current understanding and treatment. N Engl J Med 2002; 346: 257–70.
- Micieli G, Cavallini A, Marcheselli S et al. Alpha - dihydroergocryptine and predictive factors in migraine prophylaxis. Int J Clin Pharmacol Ther 2001; 39 (4): 144–51.
- Bussone G, Cerbo R, Martucci N et al. Alpha - dihydroergocryptine in the prophylaxis of migraine: a multicenter double - blind study versus flunarizine. Headache 1999; 39 (6): 426–31.
- Althaus M, Retzow A, Castell J et al. In vitro identification of the cytochrome P450 isoform responsible for the metabolism of alpha - dihydroergocryptine. Xenobiotica 2000; 30 (11): 1033–45.
- Setnikar I, Schmid K, Rovati L et al. Bioavailability and pharmacokinetic profile of dihydroergotoxine from a tablet and from an oral solution formulation. Arzneimittelforschung 2001; 51 (1): 2–6.
Supplementary files
